Clinical trials: Reflux
Gastro Esophageal Reflux
Effect of a Combination of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate on Subjects With GastroEsophageal Reflux Disease
The aim of this study is to investigate whether a 3-week treatment with an oral melt in mouth medical device, made up with hyaluronic acid, chondroitin sulphate and magnesium trisilicate, can lead to a reduction of…
- Trial name
- NCT03883074
- Testing
- hyaluronic acid with chondroitin + sulphate + magnesium trisilicate
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- SOFAR S.p.A.
Non-erosive Gastroesphageal Reflux Disease
Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease
The purpose of this study is to investigate the safety and clinical efficacy of HIP1601 in patients with Non-erosive gastroesphageal reflux disease.
- Trial name
- NCT04325620
- Testing
- HIP1601, HGP1805
- Where
- South Korea
- Volunteers
- 208 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Gastroesophageal Reflux Disease
Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease
The purpose of this study is to assess the efficacy and safety of Dexlansoprazole modified release (MR) (30 mg once daily [QD] or 60 mg QD) compared to placebo in relief of daytime and nighttime heartburn over 4 weeks in subjects…
- Trial name
- NCT00321984
- Testing
- Dexlansoprazole MR
- Where
- 153 sites in United States
- Volunteers
- 947 people
- Sponsor
- Takeda
Non-erosive Gastroesophageal Reflux Disease
Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)
The purpose of this study was to evaluate the efficacy and safety of oral TAK-438 10 mg once-daily in the treatment of non-erosive gastroesophageal reflux disease (NERD).
- Trial name
- NCT02954848
- Testing
- TAK-438 10 mg
- Where
- 30 sites in Japan
- Volunteers
- 484 people
- Sponsor
- Takeda
Repeatedly Recurring Esophagitis, Relapsing Reflux Esophagitis
Nexium Capsules RE Maintenance Specific Clinical Experience Investigation
The purpose of this study is to collect following data in patients given Nexium capsule (Nexium) in usual post-marketing use as the maintenance therapy for repeatedly recurring/relapsing reflux oesophagitis.
- Trial name
- NCT01562639
- Where
- 46 sites in Japan
- Volunteers
- 647 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Mass Balance Study of [14C]X842 in Healthy Adult Male Subjects
This study is a single-site, single-dose, non-randomized, open-label study to assess the absorption, metabolism, and excretion profile of [14C]X842 in healthy adult male subjects.
- Trial name
- NCT07107672
- Testing
- [14C]X842
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
Gastroesophageal Reflux
Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy
The purpose of this study is to determine if patients with well-controlled heartburn symptoms on twice-daily proton pump inhibitor therapy remain well-controlled after stepping down to once-daily (QD) dexlansoprazole modified…
- Trial name
- NCT00847808
- Testing
- Dexlansoprazole MR QD
- Where
- 52 sites in United States
- Volunteers
- 178 people
- Sponsor
- Takeda
Refractory Reflux Esophagitis
Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis
The purpose of this study is to evaluate the efficacy and safety of E3810 tablets in patients with Proton Pump Inhibitor-resistant reflux esophagitis.
- Trial name
- NCT00770913
- Testing
- E3810
- Where
- 54 sites in Japan
- Volunteers
- 337 people
- Sponsor
- Eisai Co., Ltd.
Gastroesophageal Reflux
Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors
This study is meant to assess the effect of IW-3718 as an added treatment to ongoing once-daily protocol pump inhibitor (PPI) treatment for patients who continue to experience symptoms of their gastroesophageal reflux disease…
- Trial name
- NCT02030925
- Testing
- IW-3718
- Where
- 10 sites in United States
- Volunteers
- 93 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
GERD
A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects
To compare pharmacokinetics, pharmacodynamics and safety after single/multiple administration of CKD-382 and D026 in healthy subjects
- Trial name
- NCT04703374
- Testing
- CKD-382(formulation I), CKD-382(formulation II), D026
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Gastroesophageal Reflux Disease
An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD Patients
The purpose of this trial is to investigate the pharmacodynamic effect on reflux parameters of SPD557 tablets (0.5 mg t.i.d., on top of PPI treatment) in patients with Gastroesophageal Reflux Disease (GERD) with persistent…
- Trial name
- NCT01370863
- Testing
- SPD557
- Where
- 15 sites in Belgium, France and 4 more
- Volunteers
- 67 people
- Sponsor
- Shire
Gastroesophageal Reflux Disease
A Study to Compare PK, PD and Safety of the AD-214 and AD-2141
A study to compare safety, pharmacokinetics and pharmacodynamics of AD-214 to AD-2141 in healthy volunteers.
- Trial name
- NCT05062876
- Testing
- AD-214, AD-2141
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Acute Coronary Syndrome, Myocardial Infarction
Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
The purpose of the COGENT-1 clinical trial is to determine whether CGT-2168 (clopidogrel and omeprazole) compared to clopidogrel is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- COGENT-1 (NCT00557921)
- Testing
- CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
- Where
- 491 sites in United States, Australia and 14 more
- Volunteers
- 5,000 people
- Sponsor
- Cogentus Pharmaceuticals
GERD
An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
This study looks at the effect on basal and pentagastrin-stimulated acid output of 40 mg Esomeprazole (Nexium) administered orally and intravenously as a 15-minute infusion to people with symptoms of Gastroesophageal Reflux…
- Trial name
- NCT00629564
- Testing
- Esomeprazole
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease
The primary objective of this study is to evaluate the pharmacokinetic profile of vonoprazan in adolescent participants with symptomatic gastroesophageal reflux disease (GERD).
- Trial name
- NCT05343364
- Testing
- Vonoprazan
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Mitral Valve (MV) Regurgitation
A Prospective, Multicenter, Single-Arm Study to Support the Clinical Evidence Base for MRace as a Treatment Option for FMR Patients With Complex M-TEER Anatomies (FR)
A pilot study to evaluate the safety and performance of the MRace System to treat severe mitral regurgitation and to gather data on its performance thereby providing guidance for future clinical development.
- Trial name
- ACCESS-MR (FR) (NCT07757607)
- Testing
- Transcatheter mitral valve repair (MRace Implant and Delivery System)
- Volunteers
- 20 people
- Sponsor
- Polares Medical SA
Gastroesophageal Reflux Disease
Drug Interaction Study Between AZD3355 and Nexium
The purpose of the study is to evaluate if AZD3355 and Nexium interact with each other or not, i.e. show the same or altered plasma concentration profiles when co-administered compared to administered alone.
- Trial name
- NCT00684190
- Testing
- AZD3355, Esomeprazole
- Where
- Sweden
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole
The primary objective of this study is to collect safety information on rabeprazole 10 mg and 20 mg in the treatment of gastroesophageal reflux disease (GERD) in children aged 12 to 16 years.
- Trial name
- NCT00132496
- Testing
- rabeprazole sodium
- Where
- 25 sites in United States
- Volunteers
- 111 people
- Sponsor
- Eisai Inc.
Gastrointestinal Health
Viome Nutritional Programs to Improve Clinical Outcomes for Gastrointestinal Conditions
US residents who have gastrointestinal issues sign the informed consent form and are screened and enrolled for this study. Participants who are enrolled complete a survey upon enrollment and are randomized into one of three arms.
- Trial name
- NCT05465629
- Testing
- VIOME Precision Nutrition Program, VIOME-designed condition-based supplements
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Viome
Gastroesophageal Reflux Disease
A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease
The aim of this study is to evaluate the pharmacokinetic (PK) profile of vonoprazan (10 or 20 mg once daily [QD]) in children ≥ 6 to < 12 years of age who have symptomatic Gastroesophageal Reflux Disease (GERD).
- Trial name
- NCT06106022
- Testing
- Vonoprazan
- Where
- 13 sites in United States
- Volunteers
- 22 people
- Sponsor
- Phathom Pharmaceuticals, Inc.